ICU Medical (ICUI) Q2 2026 Earnings Call Transcript
ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.
How this was made
The 30-second read
Why it matters
The newest actionable information is the raised and narrowed full-year adjusted EBITDA and adjusted EPS guidance, plus updated margin drivers (lower tariffs, synergy capture) and leverage trajectory toward ~2x by year-end.
Market read
Traders can update models immediately using the explicit raised guidance ranges and margin/leverage commentary, while monitoring tariff refund cadence and FDA submission timing for follow-through.
What to watch
Joint venture (Otsuka) breakeven expectations and FDA resubmission timing for the Medfusion 5000 amended package could become near-term catalysts or delays, affecting sentiment beyond the headline guidance.
Background
ICU Medical reported Q2 2026 results and discussed segment performance, integration progress, tariff impacts, and full-year guidance on its earnings call transcript.
Ticker impact
ICU Medical raised and narrowed FY adjusted EBITDA guidance to $415M-$435M and adjusted EPS to $8.60-$9.00 on the Q2 call.
Bias toward upward revisions in estimates and multiple support, with volatility around tariff refund timing and incremental tariff range.
The article provides explicit raised guidance ranges, margin and EBITDA drivers, and a stated leverage target of ~2x by year-end, which are direct inputs to trader models. However, it is a transcript and some items (tariff refunds, FDA timing) carry execution risk.
Market effects
Signals improving profitability for infusion and consumables manufacturers via tariff relief and integration synergies, potentially read-across to peers’ margin expectations.
Tariff refunds and FX headwinds (Costa Rican colon, Mexican peso) highlight sensitivity for supply chains tied to Latin America and cross-border logistics.
Tariff and IEEPA-related cash flows underscore how US trade policy can quickly affect medical device manufacturers’ earnings quality.
Counterpoint
Tariff refunds are a cash-flow tailwind, but management also flags ongoing incremental tariffs of $30M-$40M annually, which could offset the benefit if refunds slow.
Key entities
- companyICU Medical
Reported Q2 2026 results and raised full-year adjusted EBITDA and adjusted EPS guidance; discussed tariff refunds, integration synergies, and FDA-related development.
- joint_venture_partnerOtsuka
Announced a $0.5 billion investment tied to PVC-free production technologies for the U.S. market via the ICU Medical joint venture.
- executiveVivek Jain
CEO and Chairman who discussed tariff impacts, FDA submission plans, and leverage target.
- executiveBrian Bonnell
CFO who discussed logistics cost pressures and expense trends.
